You are here

Home

Successful completion of clinical trial for NorDiag's new Bullet BUGS'n BEADS(TM) kit

3 July 2009: NorDiag has fully automated the process from sample preparation of different clinical samples to the set up of the downstream amplification technologies. NorDiag's "Bullet" instrument has the capacity to process up to 100,000 isolations per year. The clinical trial has been executed at synlab,Weiden, Germany.

The BUGS'n BEADS(TM) kit has now been improved and it is a multi kit that can be applied for several organisms causing infections among others Noro virus, MRSA, VRE and Sexually transmitted infections. The advantage for the customers is that they can use the same kit for several applications. This simplifies the laboratory processes and increase ease of use. The clinical study met the criteria and the study is the basis for IVD CE marking of the new BUGS'n BEADS(TM) "Bullet" multi application kit.

"A key element of our commercialization strategy is to sell our automated solutions based on multiple use and application flexibility. Our "Bullet" instrument and applications are well positioned for screening purposes and it targets high volume markets", says Mårten Wigstøl, CEO in NorDiag.

Contact:
CEO Mårten Wigstøl, Phone: +47 91165775

About NorDiag:
NorDiag is a biotechnology company developing, manufacturing and marketing automated solutions, instruments and tests, for use in diagnostic of infectious diseases and cancer. The Company`s core competence is isolation of bacterial and human DNA from difficult clinical samples, and the Company has established a solid market share in the Scandinavian market for sexually transmitted infections. The company has similar applications for Tuberculosis, MRSA and DNA from stool. Applications for respiratory pathogens and viruses are under development. NorDiag was founded in 2003 and has its headquarters in Oslo - Norway. The Company has offices and laboratories in Stockholm - Sweden and West Chester (PA) - USA. The group has 31 man years. NorDiag is listed on Oslo Stock Exchange with the ticker NORD.

For further information - www.nordiag.com.

Read the notice in Norwegian here